TITLE:
Metastatic (Advanced) Prostate Cancer Resistant to Castration: The Time before Resistance Development and Therapeutic Measures Undertaken in Cote d’Ivoire
AUTHORS:
Kouassi Kouamé Konan Yvon, Touré Moctar, Séka Evrard Narcisse, Oumou Kimso, Traoré Kadjatou, Odo Bitti Addé, Traoré Asmaho Danielle, Kagambega Arsène Gaëtan, Adoubi Innocent
KEYWORDS:
Cancer, Prostate, Occurrence Time, Resistance
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.9 No.12,
December
10,
2018
ABSTRACT: Objective: Contribute to improving care for prostate cancer patients in Cote d’Ivoire
by identifying the average time before the development of the hormone-resistance
and inherent therapeutic strategies. Patients and Method: It was a retro
and prospective study over three years performed at the University Teaching
Hospital of Treichville in Abidjan. 84 patients with metastatic prostate
adenocarcinoma and resistant to hormone therapy were involved in the study. The
analysis of clinical records enabled us to integrate different parameters in
our study. Results: Our patients were relatively young (an average age
of 61 years) and most of them belonged to the middle socio-economic
class (50%). The resistance occurred within an average period of 9 months. The
mixing of Docetaxel and Prednisone chemotherapy was the most used method of
treatment (70% of cases). However, few patients (9.5%) received Abiraterone Acetate.
Digestive and hematologic toxicities were noticed but they could be controlled
by inherent treatment or disappear spontaneously. After nine months of
treatment, 54.24% of patients who received specific treatment were alive, but
high rates of mortality were observed as for patients who were only treated
symptomatically. Conclusion: The relatively short average time before
the development of hormone-resistance shows the aggressiveness of prostate
adenocarcinoma from black Africans. The main therapeutic standard in our
context remains Taxane-based chemotherapy with a good and fair tolerance.